Novel Antitumor Indolocarbazole Compound 6-N-Formylamino-12,13-dihydro-1,11-dihydroxy-13-β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): Induction of Topoisomerase I-mediated DNA Cleavage and Mechanisms of Cell Line-selective Cytotoxicity

Cancer Research

Volumn 55, Issue 6, 1995, Pages 1310-1315

  Yoshinari, Tomoko ^a   Matsumoto, Mami ^a   Arakawa, Hiroharu ^a   Okada, Hiromasa ^a   Noguchi, Kazuo ^a   Suda, Hiroyuki ^a   Okura, Akira ^a   Nishimura, Susumu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE; 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; APHIDICOLIN; BE 13793C; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; CELL DNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; DACTINOMYCIN; DNA DIRECTED DNA POLYMERASE ALPHA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ED 110; ENZYME INHIBITOR; ETOPOSIDE; K 252A; KT 6124; MIDOSTAURIN; PROTEIN KINASE C; RNA POLYMERASE II; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG SELECTIVITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; CARBAZOLES; DNA; DNA TOPOISOMERASES, TYPE I; DNA-DIRECTED RNA POLYMERASES; GLUCOSIDES; HUMAN; MICE; PROTEIN KINASES; TUMOR CELLS, CULTURED;

EID: 0028931509     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Stewart, A. F., and Schutz, G. Camptothecin-induccd in vivo topoisomerase I cleavages in the transcription active tyrosine aminotransferase gene. Cell, 50:1109–1117, 1987.
2. Zhang, H., Wang, J. C., and Liu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA, 85: 1060–1064, 1988.
3. Wu, H.-Y., Shyy, S. H., Wang, J. C., and Liu, L. F. Transcription generates positively and negatively supercoiled domains in the template. Cell, 53: 433–440, 1988.
4. Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J., and Reinberg, D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature (Lond.), 365: 227–232, 1993.
5. Giovenella, B. C., Steblin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Pomesil, M. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046–1048, 1989.
6. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. Evaluation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539–546, 1994.
7. Kojiri, K., Kodo, H., Yoshinari, T., Arakawa, H., Nakajima, S., Stoh, F., Kawamura, K., Okura, A., Suda, H., and Okanishi, M. A new antitumor substance, BE-13793C, produced by a Streptomycete; taxonomy, fermentation, isolation, structure determination and biological activity. J. Antibiot., 44: 723–728, 1991.
8. Yoshinari, T., Yamada, A., Umemura, D., Nomura, K., Arakawa, H., Kojiri, K., Yoshida, E., and Okura, A. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res., 53: 490–494, 1993.
9. Arakawa, H., Iguchi, T., Yoshinari, T., Kojiri, K., Suda, H., and Okura, A. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn. J. Cancer Res., 84: 574–581, 1993.
10. Homma, S. Studies on the establishment and some biological characteristics of cultured human liver cancer cell lines: their growth, functional and morphological characteristics and temperature sensitivities. Jikeikai Med. J., 32: 289–315, 1985.
11. Yamada, H., Yoshida, T., Sakamoto, H., Terada, M., and Sugimura, T. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-ki-ras by a point mutation. Biochem. Biophys. Res. Commun., 140: 167–173, 1986.
12. Yamada, H., Sakamoto, H., Taira, M., Nishimura, S., Shimosato, Y., Terada, M., and Sugimura, T. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn. J. Cancer Res., 77: 370–375, 1986.
13. Tsuruo, T. Reversal of acquired resistance to Vinca alkaloids and anthracycline antibiotics. Cancer Treat. Rep., 67: 889–894, 1983.
14. Miller, K. G., Liu, L. F., and Englund, P. T. A homogeneous type II DNA topoi-somerase from HeLa cell nuclei. J. Biol. Chem., 256: 9334–9339, 1981.
15. Drake, F. H., Zimmerman, J. P., McCabe, F. L., et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J. Biol. Chem., 262: 16739–16747, 1987.
16. Takada-Takayama, R., Tada, S., Hanaoka, F., and Ui, M. Peptide mapping of the four subunits of the mouse DNA polymerase α-primase complex. Biochem. Biophys. Res. Commun., 770: 589–595, 1990.
17. Hodo, H. G., and Blatti, S. P. Purification using polyethylenimine precipitation and low molecular weight subunit analyses of calf thymus and wheat germ DNA-dependent RNA polymerase II. Biochemistry, 16: 2334–2342, 1977.
18. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., NoCziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827–4833, 1988.
19. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107–1112, 1990.
20. Arya, S. K., and Yang, J.-T. Interaction of steroids with nucleic acids. Biochemistry, 14: 963–969, 1975.
21. Montecucco, A., Pedrali-Noy, G., Spadari, S., and Zanolin, E. DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. Nucleic Acids Res., 16: 3907–3918, 1988.
22. Sekiguchi, K., Tsukuda, M., Ase, K., Kikkawa, U., and Nishizuka, Y. Mode of activation and kinetic properties of three distinct forms of protein kinase C from rat brain. J. Biochem., 103: 759–765, 1988.
23. Takai, Y., Nakaya, S., Inoue, M., Kishimoto, A., Nishiyama, K., Yamamura, H., and Nishizuka, Y. Comparison of mode of activation of guanosine 3′:5′-monophosphate-dependent and adenosine 3′:5′- monophosphate-dependent protein kinases from silkworm. J. Biol. Chem., 251: 1481–1487, 1976.
24. Tanaka, S., Okabe, T., Chieda, S., Endo, K., Kanoh, T., Okura, A., and Yoshida, E. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase. Jpn. J. Cancer Res., 85: 253–259, 1994.
25. Akiyama, T., Kadooka, T., and Ogawara, H. Purification of the epidermal growth factor receptor by tyrosine-Sepharose affinity chromatography. Biochem. Biophys. Res. Commun., 131: 442–448, 1985.
26. Hsiang, Y.-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873–14878, 1985.
27. Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., and Tomita, F. Staurosporine, a potent inhibitor of phospholipid/Ca++ -dependent protein kinase. Biochem. Biophys. Res. Commun., 135: 397–402, 1986.
28. Kase, H., Iwahashi, K., and Matsuda, Y. K252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot., 39: 1059–1065, 1986.
29. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C., in murine and human tumor models. Cancer Res., 57: 4888–4892, 1991.
30. Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Rosel, J., Muller, M., Caravatti, G., and Matter, A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43: 851–856, 1989.
31. Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M., and Nakano, H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry, 31: 12069–12075, 1992.
32. Akinaga, S., Ashizawa, T., Gomi, K., Ohno, H., Morimoto, M., Murakata, C., and Okabe, M. Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K252a, and its mechanism of action. Cancer Chemother. Pharmacol., 29: 266–272, 1992.
33. Madden, K. R., and Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52: 525–532, 1992.